Education
About Us
Working with TipRanks
Follow Us
CSL Limited (CH:CSJ)
:CSJ
CSJ Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
CSL News
PremiumCompany Announcements
CSL’s ANDEMBRY® Gains FDA Approval for Hereditary Angioedema Treatment
PremiumCompany Announcements
CSL Limited Appoints Cameron Price as Non-executive Director
PremiumCompany Announcements
CSL Limited Announces Cessation of Securities
PremiumCompany Announcements
CSL Limited Announces Cessation of SecuritiesPremiumCompany Announcements
CSL Limited Announces Cessation of Securities
PremiumCompany Announcements
CSL Monitors U.S. Tariff Developments to Safeguard Medicine Access
PremiumCompany Announcements
CSL Limited Announces Director’s Share AcquisitionOptions Prices
Currently, No data available
---
Ownership Overview
0.05% Insiders
4.99%
Mutual Funds
<0.01% Other Institutional Investors
86.72% Public Companies and
Individual Investors
CSJ FAQ
What was CSL Limited’s price range in the past 12 months?
Currently, no data Available
What is CSL Limited’s market cap?
Currently, no data Available
When is CSL Limited’s upcoming earnings report date?
CSL Limited’s upcoming earnings report date is Aug 19, 2025 which is in 54 days.
How were CSL Limited’s earnings last quarter?
CSL Limited released its earnings results on Feb 11, 2025. The company reported $3.511 earnings per share for the quarter, missing the consensus estimate of $3.613 by -$0.101.
Is CSL Limited overvalued?
According to Wall Street analysts CSL Limited’s price is currently Undervalued.
Does CSL Limited pay dividends?
CSL Limited pays a Annually dividend of $1.108 which represents an annual dividend yield of 1.75%. See more information on CSL Limited dividends here
What is CSL Limited’s EPS estimate?
CSL Limited’s EPS estimate is 1.75.
How many shares outstanding does CSL Limited have?
Currently, no data Available
What happened to CSL Limited’s price movement after its last earnings report?
CSL Limited reported an EPS of $3.511 in its last earnings report, missing expectations of $3.613. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of CSL Limited?
Currently, no hedge funds are holding shares in CH:CSJ
CSL Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$165.53 (― Downside)
$165.53 (― Downside)
Blogger Sentiment
Bullish
CH:CSJ Sentiment 77%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $32.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.96%
12-Months-Change
Fundamentals
Return on Equity
15.38%
Trailing 12-Months
Asset Growth
3.06%
Trailing 12-Months
Company Description
CSL Limited
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.
CSJ Company Deck
CSJ Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive sentiment, with strong financial performance led by CSL Behring and a promising outlook despite challenges in CSL Seqirus and specialty products due to external market conditions.Read More>CSJ Stock 12 Month Forecast
Average Price Target
$165.53
Clinuvel Pharmaceuticals
―
Mesoblast Limited
―
Neuren Pharmaceuticals Limited
―
Immutep Ltd
―
Telix Pharmaceuticals Ltd.
―